TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.

firtecan pegol (PEG-SN38) - Belrose

Trodelvy (sacituzumab govitecan-hziy) - Gilead

PLX038 - ProLynx

https://meetings.asco.org/abstracts-presentations/238279/

Luc Cabel; Delphine Loirat; Jerome Martin Babau; Diana Bello; Jean-Yves Pierga; Florence Lerebours; Cyrine Ezzili; Frederique Berger; Francois Clement Bidard

Apr 25, 2024